MedUni Vienna: Neuroblastoma: improved treatment prospects in future
Study identifies new treatment option using targeted cancer medicine
(Vienna, 03 December 2019) Neuroblastoma is a rare form of malignant tumour, primarily affecting children under the age of six. A research team led by molecular pathologist Lukas Kenner from MedUni Vienna's Department of Pathology has now discovered, through genome sequencing, that the protein ALK and the cancer gene PIM1 are involved in the development of this tumour. The study found that targeted cancer treatment using an ALK inhibitor in combination with a PIM1 inhibitor can increase the chances of survival of children with an unfavourable prognosis. The study has now been published in the leading journal "Nature Communications".
One of the commonest and most lethal types of solid childhood cancer is neuroblastoma, a tumour of the peripheral nervous system. It occurs in approximately 10% of childhood cancer cases, with 90% of the sick children being under the age of six. The course of the disease can differ greatly, depending upon the clinical picture and genetic mutation of the cancer cells. For example, the tumour can spontaneously regress but equally there can be metastasis and recurrences with an unfavourable prognosis.
The standard treatment used so far involves surgery, high-dose chemotherapy and/or radiotherapy but, in the event of recurrence, the chances of 5-year survival are not very high. For a long time now, the research team led by molecular pathologist Lukas Kenner from MedUni Vienna's Department of Pathology and Head of the Division of Laboratory Animal Pathology at Vienna University of Veterinary Medicine has been studying a specific protein, anaplastic lymphokinase ALK, in relation to the development of neuroblastoma in children. This protein is found to have mutated in approximately 14% of these young patients. Small molecular ALK inhibitors, which are already approved for the treatment of ALK-positive lung cancer, are currently undergoing clinical trials for neuroblastoma patients with the mutated ALK gene. Preclinical studies confirm therapeutic efficacy, but some tumours develop resistance to ALK inhibitors.
The studies are therefore focusing on developing new treatment options on a molecular biological basis. It is being attempted to exploit molecular structures that are essential for tumour development for therapeutic purposes. Working with Suzanne Turner, Division of Cellular and Molecular Pathology, Addenbrooke's University Hospital, Cambridge UK, Kenner's team tested the therapeutic effect of inhibitors for ALK mutations in children with recurrent neuroblastoma.
Genome sequencing of these patients revealed that the cancer gene PIM1 is also activated in neuroblastoma. A therapeutic approach now lies in deactivating this protein and this can be done using a targeted cancer therapy in the form of combined administration of ALK- and PIM1 inhibitors. At the moment, there are no drugs licensed specifically for PIM1, but preclinical studies are being conducted with Suzanne Turner to investigate PIM1 and ALK inhibitors.
Service: Nature Communications
The targetable kinase PIM1 drives ALK inhibitor resistance in high-risk neuroblastoma independent of MYCN status. Ricky Trigg, Liam Lee , Nina Prokoph , Leila Jahangiri , C Patrick Reynolds , G.A. Amos Burke, Nicola Probst, Miaojun Han, Jamie Matthews, Hong Kai Lim, Eleanor Manners, Sonia Martinez, Joaquin Pastor, Carmen Blanco-Aparicio, Olaf Merkel, Ines Garces de los Fayos Alonso, Petra Kodajova, Simone Tangermann, Sandra Hogler , Ji Luo, Lukas Kenner, Suzanne D. Turner, doi.org/10.1038/s41467-019-13315-x
Contact:
Medizinische Universität Wien
Mag. Johannes Angerer
Leiter Kommunikation und Öffentlichkeitsarbeit
+431 40160 - 11 501
Mobil: +43 664 800 16 11 501
johannes.angerer@meduniwien.ac.at
http://www.meduniwien.ac.at